X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

12 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Prices $65.0 Million Public Offering

07 Dec 2022 07:43:05 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Proposed Public Offering

06 Dec 2022 17:26:02 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome

29 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at Stifel Healthcare Conference

08 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

03 Nov 2022 05:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022

20 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

27 Sep 2022 06:50:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

31 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd Annual Growth Conference

08 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

04 Aug 2022 06:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022

26 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

20 Jul 2022 15:10:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2022 15:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months

30 Jun 2022 18:52:34 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor

16 May 2022 05:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

12 May 2022 05:05:00 By Nasdaq GlobeNewswire